PEPTONIC medical

Peptonic Medical AB is a Swedish biomedical company established in 2009, focused on the research, development, and commercialization of products for women's health. Publicly traded on the Spotlight Stock Market in Stockholm since 2014, the company is strategically positioned to address common intimate health issues through a portfolio of clinically proven, self-care products. The company's growth plan centers on expanding its geographical footprint, particularly in the U.S. and Europe, alongside continuous product portfolio enhancement through in-house development and strategic acquisitions.

The core of Peptonic's business is its proprietary product line sold under the VagiVital® and Vernivia brands. These products are designed to empower women to diagnose, treat, and prevent common intimate medical conditions independently. The business model involves establishing reference markets in the Nordics through sales in physical and online pharmacies, as well as its own e-commerce channels. International expansion is achieved through collaborations with local distributors and licensing agreements with partners who sell the products under their own brands. In a strategic move to bolster its U.S. presence, Peptonic established a wholly-owned subsidiary, Peptonic Medical Inc., in April 2025 to manage direct-to-consumer sales, while its other subsidiary, Common Sense Marketing Inc., handles white-label partnerships with major retailers like Bayer, CVS, Walgreens, and Walmart.

The flagship product, VagiVital® AktivGel, is a hormone-free, crystal-clear gel for treating symptoms of vaginal atrophy such as dryness, itching, and pain during intercourse. Its efficacy has been demonstrated in clinical studies, showing it relieves symptoms on par with prescription estrogen-based products. The VagiVital® line also includes a moisturizing cleanser and VagiVital AL, a self-test for detecting amniotic fluid leakage during pregnancy. Originally focused on developing an oxytocin-based pharmaceutical, Vagitocin®, for vaginal atrophy, the company has leveraged the patented gel base from that research for its current commercial products. This strategic pivot allows Peptonic to operate in the space between prescription medications and standard self-care, offering clinically validated solutions directly to consumers.

Keywords: women's health, medtech, biomedical, self-care products, VagiVital, vaginal atrophy, hormone-free treatment, intimate health, femtech, clinical diagnostics, e-commerce healthcare, pharmaceutical development, OTC products, medical devices, Swedish biomedical, Spotlight Stock Market, intimate care, non-prescription, women's wellness, vaginal dryness